Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review

Abstract

Background and Objective Precision (stratified or personalised) medicine is underpinned by the premise that it is feasible to identify known heterogeneity using a specific test or algorithm in patient populations and to use this information to guide patient care to improve health and well-being. This study aimed to understand if, and how, previous economic evaluations of precision medicine had taken account of the impact of capacity constraints. Methods A meta-review was conducted of published systematic reviews of economic evaluations of precision medicine (test–treat interventions) and individual studies included in these reviews. Due to the volume of studies identified, a sample of papers published from 2007 to 2015 was collated. A narrative analysis identified whether potential capacity constraints were discussed qualitatively in the studies and, if relevant, which quantitative methods were used to account for capacity constraints. Results A total of 45 systematic reviews of economic evaluations of precision medicine were identified, from which 222 studies focusing on test–treat interventions, published between 2007 and 2015, were extracted. Of these studies, 33 (15%) qualitatively discussed the potential impact of capacity constraints, including budget constraints; quality of tests and the testing process; ease of use of tests in clinical practice; and decision uncertainty. Quantitative methods (nine studies) to account for capacity constraints included static methods such as capturing inefficiencies in trials or models and sensitivity analysis around model parameters; and dynamic methods, which allow the impact of capacity constraints on cost effectiveness to change over time. Conclusions Understanding the cost effectiveness of precision medicine is necessary, but not sufficient, evidence for its successful implementation. There are currently few examples of evaluations that have quantified the impact of capacity constraints, which suggests an area of focus for future research. Electronic supplementary material The online version of this article (10.1007/s40273-019-00801-9) contains supplementary material, which is available to authorized users.

Implementing Interventions with Varying Marginal Cost-Effectiveness: An Application in Precision Medicine

“…These approaches could use static models with costs and benefits that are described as a function of implementation levels and producing estimates of cost-effectiveness at different levels or dynamic, multicohort models to capture the impact of changing marginal costs and benefits over time. 18…”

“…A number of barriers (or capacity constraints) have been identified that may hinder fully comprehensive and inclusive access to the introduction of precision medicine: lack of sufficient laboratories to perform testing, logistical issues with coordinating testing and treatment, and sufficient numbers of trained laboratory staff, allied health care professionals, and clinicians. 15–18 Concerns about the capacity of the National Health Service in England (NHS England) to provide the required EGFR mutation testing were raised during a NICE Technology Appraisal of gefitinib for non–small cell lung cancer. 19 Despite assurances at the time of the appraisal, subsequent evidence in 2014 suggested that only around 50% of eligible patients were receiving EGFR testing.…”

Understanding barriers to the introduction of precision medicine in non-small cell lung cancer: a qualitative interview study

“…The interview schedule was piloted with two clinicians before study recruitment began. The interview schedule for service providers (see extended data 25 ), and service commissioners (see extended data 26 ) were, informed by a systematic review of previous economic evaluations of precision medicine (including health technology assessments) 27 and consultation with two expert clinical advisors who are lung oncologists. The core questions for each of the two interview schedules were similar.…”

Situación actual del cáncer de colon en Chile: una mirada traslacional

“…Aun cuando se han desarrollado esfuerzos menos sistematizados respecto a la utilización de las nuevas clasificaciones moleculares y su relación con nuevas drogas, este conocimiento generado, nos debe llamar a buscar el porcentaje de KRAS mutado en nuestros pacientes con CCR. Esto, no solo permitiría optimizar clínicamente la indica-ción de las drogas biológicas, sino que además, este paradigma de la medicina de precisión, permitiría realizar planificación sanitaria moderna, a partir de nuestra propia epidemiología molecular, lo que podría "teóricamente" tener un efecto fármaco-económico positivo, sin embargo, hacen falta más estudios para dilucidar este intrincado punto 49,50 .…”